A Multi-center, Open-label Comparison Study of a 13C-uracil Breath Test Versus 99mTechnetium Sulfur Colloid Gastric Emptying Scintigraphy to Evaluate Normal, and Delayed Gastric Emptying Time in Dyspeptic Subjects

This study is a multi-center, open-label comparison study and aimed to evaluate the preliminary performance of this 13C-uracil GEBT to examine its abilities of identifying abnormal (delayed) gastric emptying rates in subjects.

开始日期2013-07-01

申办/合作机构

Otsuka Pharmaceutical Co., Ltd.

[+1]

JPRN-UMIN000013098

/ CompletedN/AIIT

A phase II trial of uracil ointment for the prevention of capecitabine induced hand-foot syndrome (HFS): . - P2 trial of uracil ointment

开始日期2012-10-01

申办/合作机构

Kyoto Prefectural University of Medicine

EUCTR2009-017620-11-NL

/ Unknown statusN/AIIT

Onderzoek naar de farmacokinetiek van uracil na orale toediening bij patiënten met colorectaal carcinoom. - KINURA-2

开始日期2011-06-14

申办/合作机构-

100 项与尿嘧啶相关的临床结果

登录后查看更多信息

100 项与尿嘧啶相关的转化医学

登录后查看更多信息

100 项与尿嘧啶相关的专利（医药）

登录后查看更多信息

1,643

项与尿嘧啶相关的文献（医药）

2025-12-01·CANCER CHEMOTHERAPY AND PHARMACOLOGY

Plasma clearance of 5-fluorouracil is more influenced by variations in glomerular filtration rate than by uracil concentration

Article

作者: Royer, Bernard ; Collas, Laurine ; Goulaieff, Léa ; Bengrine-Lefevre, Leïla ; Goirand, Francoise ; Grisard, Maelle ; Ghiringhelli, François ; Schmitt, Antonin ; Vincent, Julie ; Matheux, Alice

OBJECTIVES:

The use of plasma uracil measurements to detect dihydropyrimidine dehydrogenase (DPD) deficiency is one of the methods for preventing toxicities associated with fluoropyrimidines, including 5-Fluorouracil (5-FU). Unfortunately, this measurement is subject to variations, that may lead to unnecessary dosage reductions and therefore to a reduced efficacy of treatment. Recently, new factors such as hepatic and renal impairment have been proposed as also influencing uracil concentration. The aim of our study was therefore to study the influence of renal or hepatic function on 5-FU clearance.

PATIENTS AND METHODS:

This was a retrospective study, using patients treated with 5-FU between September 1, 2018 to December 1, 2022 in a French Clinical Cancer Center. Patients were included after treatment with 5FU and therapeutic monitoring of 5FU concentrations after each course of chemotherapy. For each patient, DPD phenotyping by uracil concentration measurement was determined before the first course of 5FU. Blood samples were then taken the day after the start of the 5-FU infusion, between 8 and 10 am, for the first three cycles of 5-FU. With the exception of uracil concentration, which was determined only once, the various data were recorded for each course of 5FU chemotherapy performed. Patients with incomplete information (missing one of the above parameters) were excluded from the database.

RESULTS:

We included 227 patients, corresponding to 227 uracil concentrations and 575 5-FU concentrations. In an original development, our results show for the first time that 5-FU clearance was proportionally correlated with eGFR (calculated according to CKD-EPI formula). Although we failed to demonstrate this hypothesis significantly, we observed that 5-FU clearance may be more dependent on eGFR than on uracil concentration for low uracil concentrations values.

CONCLUSION:

Our study reinforces the still poorly accepted idea of the value of focusing on eGFR in 5-FU dose adjustment.

2025-01-01·ANTI-CANCER DRUGS

Synergistic combination effect of the PCA-1/ALKBH3 inhibitor HUHS015 on prostate cancer drugs in vitro and in vivo

Article

作者: Mabuchi, Miyuki ; Tanaka, Akito ; Tsujikawa, Kazutake

Prostate cancer antigen-1/ALKBH3, a DNA/RNA demethylase of 3-methylcytosine, 1-methyladenine (1-meA), and 6-meA, was found in prostate cancer as an important prognostic factor. Additionally, 1-meA has been associated with other cancers. The ALKBH3 inhibitor HUHS015 was found to be effective against prostate cancer both in vitro and in vivo. Herein, we investigated the effect of HUHS015 in combination with drugs for prostate cancer approved in Japan (including bicalutamide, cisplatin, mitoxantrone, prednisolone, ifosfamide, tegafur/uracil, docetaxel, dacarbazine, and estramustine) by treating DU145 cells with around IC50 value concentrations of these drugs for 3 days. Additionally, the cells were observed for additional 9 days after drug removal. Combination treatment with dacarbazine, estramustine, tegafur/uracil, and HUHS015 showed a slight additive effect after 3 days. After drug washout of them and mitoxantrone, the combined effects and levels were enhanced and sustained, although the effects of each treatment alone declined. HUHS015 combined with cisplatin or docetaxel elicited synergistic and sustained effects. In vivo, combining HUHS015 and docetaxel, the first chemotherapeutic agent for castration-resistant prostate cancer, showed notable effects in the DU145 xenograft model. In conclusion, HUHS015 exhibited a synergistic effect with docetaxel and drugs acting on DNA in vitro, even after drug removal. Since cancer chemotherapy is typically administered during rest periods due to its high toxicity, combining it with an ALKBH3 inhibitor could be a promising strategy for enhancing cancer treatment, as it can elicit an additive effect during treatment, allowing dosage reduction, and synergistically sustain the effect after drug washout during rest periods.

2025-01-01·BIOORGANIC CHEMISTRY

Rational design, synthesis, biological evaluation, molecular docking, and molecular dynamics of substituted uracil derivatives as potent anti-cancer agents

Article

作者: Basiony, Ebtessam A ; Hassan, Nasser A ; Hassan, Allam A ; Mansour, Hayam ; Abdel-Rahman, Adel A-H ; Arafa, Reem K ; Elsawalhy, Mohamed

An efficient synthesis of a series of uracil analogous was performed to obtain new potential anticancer agents. The cytotoxic effect of the synthesized derivatives was assessed in vitro against three cancer cell lines, namely hepatic cancer (HepG-2), colon cancer (HCT-116), and breast cancer (MCF-7). Among the tested compounds, 5, 11 and 15 stood as potent uracil derivatives with pan cytotoxicity against the 3 cell lines out-performing the reference compound 5-FU. Furthermore, selected compounds underwent thymidylate synthase (TS) enzyme inhibition assay and demonstrated effective inhibition of the enzyme's catalytic activity. Thereafter, flow cytometric apoptosis and protein expression of pro- and anti-apoptotic markers Bax, BCL-2, PI3K, and STAT1 proteins assays were performed employing the most active compound on the respective most responsive cell line and compounds demonstrated effectiveness in inducing apoptosis in the treated cell lines. Finally, in silico studies encompassing molecular docking and molecular dynamics studies were also conducted to predict the interaction mechanisms and stability of the active compounds within the active site of their biological target TS.

项与尿嘧啶相关的新闻（医药）

2024-12-29

·癌度

肿瘤抑制率最高提升13倍！它可能开启癌症治疗新时代

癌度优选 · 让肿瘤康复更简单化疗是用化学合成的药物来治疗疾病，为目前治疗肿瘤及某些自身免疫性疾病的主要手段之一，透过干扰细胞中的 DNA、RNA 或蛋白质合成来影响癌细胞的生成。但是在治疗中，普遍会为患者带来明显的恶心、呕吐、腹泻等副作用，成为很多患者和家属抗拒化疗的主要原因。如何能够在使用化疗方式的同时，又尽可能的减毒增效，是科学家们也一直在努力的方向。好的消息是，益生菌有较为明显的效果。特别是对于胃肠道肿瘤中常用的化疗药5-氟尿嘧啶和卡培他滨，益生菌可能是减毒增效的一个有效方法。帮助患者完成治疗 5-氟尿嘧啶（5-FU）和卡培他滨（5-FU的前体药物，可以在体内代谢为5-FU）都是胃肠道肿瘤治疗的常用药物，但也是非常容易引起腹泻的一类化疗药。在肠道中，5-FU不但会对肠粘膜造成急性损伤，还能诱导肠隐窝细胞（肠道的干细胞）有丝分裂停滞，使得未成熟分泌性肠隐窝细胞数量增加。两种因素都会导致更多的液体进入肠腔，引起严重的腹泻。肠粘膜的损伤还会增加感染的风险，进一步加重腹泻的问题。而益生菌正是应对肠道感染和腹泻的有效方法。 2020年一项研究中，76名接受5-FU或卡培他滨化疗的患者同时服用了益生菌产品Kefibios ®，最终只有5人（6.5%）出现严重腹泻（3~4级），17人（22%）在6周期治疗中完全没有出现腹泻。研究人员估计，Kefibios ®让严重腹泻的绝对风险降低了10%[1]。研究中轻度腹泻和严重腹泻的发生率促进癌细胞凋亡增强治疗效果除了减少治疗副作用外，益生菌还能在一定程度上提高化疗的疗效。 2010年一项研究就发现，2种益生菌的混合物可以让5-FU诱导结直肠癌细胞凋亡的能力增强40%[2]。另外，还有研究发现5-FU具有一定的免疫诱导作用，可以清除肿瘤中的髓系免疫抑制细胞，增强T细胞对肿瘤的杀伤[3]。益生菌也可以通过增强抗肿瘤免疫反应，来强化5-FU的化疗效果。益生菌增强5-FU诱导癌细胞凋亡的能力不久前，中国科学院上海药物研究所的一组科学家就尝试将卡培他滨搭载在益生元（益生菌的食物）木聚糖为基础的纳米颗粒上，在化疗的同时促进益生菌的生长[4]。小鼠试验中，这种全新的给药形式明显增加了肿瘤中的药物积累，同时促进了益生菌的生长，强化了抗肿瘤免疫。相比于单独使用卡培他滨，搭载在木聚糖上的卡培他滨对小鼠结直肠癌的抑制率从5.3%提高到了71.8%，中位生存期也从14天延长到了33.5天。益生元纳米载体显著提高了卡培他滨对小鼠结直肠癌的抑制能力益生菌在癌症治疗中的作用正在逐渐得到重视，具有开启癌症治疗新时代的潜力。目前也有很多益生菌的临床试验正在进行，将这些成果从实验室转化到临床。癌度优选专为放化疗患者定制的乐愈达优护益生菌包含8种不同的复合益生菌菌株，其中植物乳杆菌、嗜酸乳杆菌、鼠李糖乳杆菌等都被发现有增强化疗疗效的作用。相信在化疗的路上，乐愈达优护益生菌会是您的“好帮手”，想了解更多信息可以扫描下方二维码联系客服咨询：参考文献： [1]. Ghidini M, Nicoletti M, Ratti M, et al. Lactobacillus kefiri LKF01 (Kefibios®) for prevention of diarrhoea in cancer patients treated with chemotherapy: a prospective study[J]. Nutrients, 2021, 13(2): 385. [2]. Baldwin∗ C, Millette∗ M, Oth D, et al. Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis[J]. Nutrition and cancer, 2010, 62(3): 371-378. [3]. Mathew A A, Zakkariya Z T, Ashokan A, et al. 5-FU mediated depletion of myeloid suppressor cells enhances T-cell infiltration and anti-tumor response in immunotherapy–resistant lung tumor[J]. International Immunopharmacology, 2023, 120: 110129. [4]. Lang T, Zhu R, Zhu X, et al. Combining gut microbiota modulation and chemotherapy by capecitabine-loaded prebiotic nanoparticle improves colorectal cancer therapy[J]. Nature Communications, 2023, 14(1): 4746.

微生物疗法

2024-12-11

·北京铭道医疗

百万粉丝网红确诊直肠癌，9次化疗无效！新型NK细胞疗法或是新突破！

近日，拥有百万粉丝的网红“咖啡”发视频称，自己确诊直肠癌6个多月后决定放弃化疗。她说自己已经化疗9次了，但是复查结果显示没起作用，同时身体已经吃不消，所以选择放弃化疗。此前也有多位名人因肠癌去世。去年3月28日日本著名作曲家、音乐人坂本龙一在东京都内医院病逝，终年71岁，早在2014年，坂本龙一就被诊断为咽喉癌，2020年6月又被诊断出罹患直肠癌，电影《黑豹》男演员查德维克·博斯曼也是罹患结肠癌去世，终年43岁。直肠癌，听起来好像离我们很遥远，但实际上，它就像那个潜伏在暗处的“敌人”。2020年世界卫生组织国际癌症研究机构（IARC）癌症统计，中国新发结直肠癌患者超55万，占世界结直肠癌患者新发病例的28.8%，死亡患者超28万，占世界结直肠癌死亡人数的30.6%。什么是结直肠癌？结直肠癌又称为“大肠癌”，是指大肠上皮来源的癌症，包括结肠癌与直肠瘟，病理类型以腺癌最为常见，极少数为鳞癌。早期症状不明显，随着癌肿的增大而表现排便习惯改变、便血、腹泻、腹泻与便秘交替、局部腹痛等症状，晚期则表现贫血、体重减轻等全身症状。 ▍ 结直肠癌的治疗现状结直肠癌治疗手段有手术治疗、化疗、靶向治疗、放疗、免疫治疗等，其中手术是结直肠癌治疗最主要的治疗手段，特别是对早期结直肠癌而言，外科手术能够对局部病灶进行彻底清除，达到“斩草除根”的治疗效果。自上世纪40年代化疗被引入临床以来，它挽救了无数患者的生命。然而，其弊端同样显而易见。化疗药物的机制是破坏快速分裂的细胞，这种方式虽然可以杀死癌细胞，但也对正常的快速分裂细胞造成伤害，如毛囊细胞、胃肠道上皮细胞和骨髓造血细胞。结果是患者不仅要承受疾病本身的痛苦，还要忍受脱发、恶心呕吐、免疫力低下等一系列副作用。免疫细胞在直肠癌治疗中应用与化疗的“大规模轰炸”相比，免疫细胞疗法更像是精准打击的“狙击手”。它通过激活患者自身的免疫系统，有针对性地清除癌细胞，同时尽量减少对正常组织的伤害。免疫细胞疗法的核心在于调动人体自身的免疫系统，对癌细胞进行定点清除。直肠癌作为实体瘤的一种，传统治疗以手术、化疗和放疗为主。然而，免疫细胞疗法在这一领域也展现出了潜力。自然杀伤（Natural killer，NK）细胞是先天免疫系统的淋巴细胞，属于固有淋巴细胞（innate lymphoid cells，ILCs）。NK细胞主要存在于血液和组织中，NK细胞具有识别肿瘤细胞和感染病毒细胞的能力，能直接攻击这些细胞，并参与多种细胞免疫应答的调节。随着对NK细胞的研究深入，科学家们广泛探究了NK细胞的重要性和潜力，特别是在抗癌方面，已经开发出针对NK细胞的治疗策略。 ▍ NK细胞治疗结直肠癌新疗法 01 在越南时代城国际医院发表于《国际分子科学杂志》上的一篇题为“Evaluating the Safety and Quality of Life of Colorectal Cancer Patients Treated by Autologous Immune Enhancement Therapy (AIET) in Vinmec International Hospitals”报道中，研究者评估了12例（8名男性和4名女性） III 期和 IV 期结直肠癌患者，接受不同数量的自体免疫细胞输注后的安全性、有效性以及生存期延长等情况。研究结果进行了评估总结，参与研究的受试患者的平均生存期，与入组时的预估生存期相比，存活率提高了约1.8倍。 02 Cancer Reports发表的临床案例证实NK细胞治疗可以抑制肠癌患者术后复发转移。 ▲ 图源 | onlinelibrary.wiley.com 一位64岁女性，因肠梗阻和带血腹泻史就医入院，患者接受了横结肠切除术，术后病理报告显示横结肠腺癌，淋巴结累及阳性(III期)。术后每2周进行FOLFOX辅助化疗方案(5-氟尿嘧啶、亚叶酸钙和奥沙利铂)输注，持续6个月。同时因为患者具有多种过敏史导致了史蒂文约翰逊综合征（药物导致的一种可能危及生命的严重不良反应），患者无法接受化疗。术后6个月PET随访显示，患者肠癌复发。经医生与患者沟通决定尝试NK细胞治疗。患者接受NK细胞治疗2个周期，二次治疗间隔3个月。PET扫描随访3年发现没有发生复发的情况，并且患者对治疗耐受良好，没有免疫相关的不良反应。并且在结肠癌手术后3年的临床随访中，患者可以很好地进行日常活动。 03 一项单臂、开放、剂量递增的单中心的初期临床研究(NCT03415100)来评估NKG2DCAR-NK细胞治疗的安全性和可行性，入组3例经标准治疗失败的腹膜转移性结直肠癌患者。研究发现NKG2D-DAP12CAR-NK细胞比NKG2D-CD3ζCAR-NK细胞呈现更强的IFN-γ分泌能力和细胞毒性免疫反应。在人结直肠癌NSG小鼠模型中显示了NKG2DpCAR-NK细胞治疗组和对照组相比具有显著的抑瘤效果，并有效延长中位生存时间。随后，采用局部输注NKG2DpCAR-NK的方式治疗了3例转移性结直肠癌患者。前两例患者腹腔输注低剂量CAR-NK细胞后，可观察看腹水生成量减慢以及腹水样本中肿瘤细胞的数量急剧减少。第三例肝转移瘤患者采用超声引导下瘤内经皮注射和腹腔内灌注方式输注CAR-NK细胞后，多普勒超声可见肝部肿瘤快速缩小，PET-CT提示经治疗的肝病灶为完全代谢反应。3例患者在治疗过程中均无出现3级或以上的不良事件。研究结果初步显示NKG2DmRNACAR-NK细胞局部输注治疗转移性结直肠癌患者具有安全性和可行性，为肿瘤免疫治疗提供了一种新的策略。目前，NK细胞治疗在结直肠癌治疗中仍处于研究和临床试验阶段，但已经显示出潜力。一些初步研究结果表明，NK细胞疗法在晚期直肠癌患者中具有显著的治果，可以减小肿瘤负荷，缓解症状，延长生存期。我们有理由相信，这一新兴的免疫疗法将为直肠癌患者带来新的希望，改善他们的生存质量，并提高康复机会。未来，或许不久的将来，我们能够看到免疫细胞疗法彻底改变癌症治疗的版图，让更多的患者从中受益，真正享受到“超长待机”的健康生活。免责申明：文章来源网络仅供分享，不构成任何临床诊断建议，我们尊重原创，也注重分享，图文素材来源于网络，如有违规或侵权，请及时联系我们会立即做出删除

细胞疗法免疫疗法临床研究

2024-12-02

·ioncology

SABCS 2024丨盛幕将启，中国专家入选壁报展示（Poster Session 1）

点击蓝字，关注我们编者按：第47届圣安东尼奥乳腺癌研讨会（SABCS）将于当地时间2024年12月10日至13日在美国得克萨斯州圣安东尼奥举行。SABCS是全球最大的乳腺癌领域盛会，来自102个国家的超过1万名注册参会者将在为期四天的会议中展示1886篇被接受的论文摘要。肿瘤瞭望特别整理中国专家被收录的壁报内容，以飨读者。（注：因官网未公布详细作者单位，如有遗漏或错误，欢迎留言指正。） Poster Session 1 日期：12月11日时间：12:30～2:00 p.m 地点：Halls 2-3 P1-01-04：EPLIN and EPLIN responsive protein APOC3 in breast cancer EPLIN及其应答蛋白APOC3在乳腺癌中的作用报告作者：Cai Wang P1-02-12: Prospective phase II study on the efficacy and safety of hetrombopag for the treatment of cancer therapy-induced thrombocytopenia in patients with breast cancer 在乳腺癌患者中应用海曲泊帕治疗癌症治疗诱导的血小板减少症的有效性和安全性的前瞻性II期研究报告作者：Hanfang Jiang P1-02-18: Cancer-Associated Fibroblast-Mediated Suppression of T Cell Activity as a mechanism of Resistance to Immunoradiotherapy in Breast Cancer 癌症相关成纤维细胞介导的T细胞活性抑制作为乳腺癌免疫放疗抵抗的机制报告作者：Rongrong Wu P1-04-04: evelopment and validation of a nomogram for axillary lymph node metastasis risk in breast cancer 乳腺癌腋窝淋巴结转移风险列线图的建立和验证报告作者：Xiaoyun Mao P1-04-12: Optimizing Tolerability of Pyrotinib in HER2-Positive EarlyStage High-Risk Breast Cancer: A Multicenter, Randomized, ThreeCohort Study 优化吡咯替尼治疗HER2阳性早期高危乳腺癌的耐受性：一项多中心、随机、三队列研究报告作者：Qiao Cheng P1-04-22: Loss of SMAD4 Drives Breast Cancer Invasion and Metastasis through E2F1-Mediated Activation of the PEG10-ERK Axis SMAD4缺失通过E2F1介导的PEG10-ERK轴激活驱动乳腺癌的侵袭和转移报告作者：Dan Shu P1-04-25: Fast and accurate detection of tumor-immune cell interactions with deep learning 利用深度学习快速准确地检测肿瘤-免疫细胞相互作用报告作者：Huiping Liu P1-05-07: Expression of ATP6AP2 in clinical breast cancer and the prognostic and therapeutic value in ERBB2 subtype of breast cancer ATP6AP2在临床乳腺癌中的表达及其在ERBB2亚型乳腺癌中的预后和治疗价值报告作者：Jia Tong P1-05-24: Biomarkers and Spatial Determinants of SHR-A1811 Efficacy in Neoadjuvant Treatment for HER2-Positive Breast Cancer SHR-A1811在HER2阳性乳腺癌新辅助治疗中疗效的生物标志物和空间决定因素报告作者：Zhi-Ming Shao P1-05-27: Analytical comparison of tissue-based next-generation sequencing assays for the detection of PIK3CA, AKT1, and PTEN tumor alterations in breast cancer 基于组织的二代测序检测乳腺癌中PIK3CA、AKT1和PTEN肿瘤改变的分析比较报告作者：Xiaodun Li P1-06-04: Psychological stress and its correlations to patients with acute lymphedema after breast cancer surgery 心理应激与乳腺癌术后急性淋巴水肿的相关性研究报告作者：Li-Chen Tang P1-06-06: Oral cyclophosphamide-induced hemorrhagic cystitis from metronomic Cyclophosphamide/Methotrexate/5-Fluorouracil for treatment of synchronous bilateral breast cancer – A case report 口服环磷酰胺导致出血性膀胱炎：一例应用节拍化疗方案环磷酰胺/甲氨蝶呤/5-氟尿嘧啶治疗同期双侧乳腺癌的病例报告报告作者：Jina Yun P1-06-24: Single-cell RNA sequencing reveals the role of HSPA1B+ immune cells in breast cancer microenvironment remodeling during neoadjuvant chemotherapy 单细胞RNA测序揭示HSPA1B+免疫细胞在乳腺癌新辅助化疗微环境重塑中的作用报告作者：Zihan Zhai P1-06-29: Targeting NRP1 reduces triple-negative breast cancer lung metastasis and improves immunotherapy efficacy 靶向NRP1可降低三阴性乳腺癌肺转移，并提高免疫治疗疗效报告作者：Zhuxi Duan P1-07-20: Mechanism of miR-221-3p/PARP1 regulating the progression of triple-negative breast cancer through the NF-κB pathway miR-221-3p/PARP1通过NF-κB通路调控三阴性乳腺癌进展的机制报告作者：Qianqian Lei P1-07-21: Efficacy of CDK4/6 Inhibitor Abemaciclib in Metastatic Triple-Negative Breast Cancer CDK4/6抑制剂阿贝西利治疗转移性三阴性乳腺癌的疗效报告作者：Chuling Zhuang P1-07-25: E3 ubiquitin-protein ligase RNF40 promotes triplenegative breast cancer progression and metastasis by promoting TRIM28 expression and stabilizing TWIST1 protein E3泛素蛋白连接酶RNF40通过促进TRIM28表达和稳定TWIST1蛋白促进三阴性乳腺癌的进展和转移报告作者：Junjiang Fu P1-07-28: Real-World Study on Efficacy and Safety of SG Alone and Combined with Immunotherapy in Metastatic Triple Negative Breast Cancer Patients SG单药及联合免疫治疗转移性三阴性乳腺癌患者的疗效和安全性的真实世界研究报告作者：Jianli Zhao P1-08-02: HIF-1-dependent expression of integrin β3 incorporated into extracellular vesicles promotes metastasis of breast cancer cells to the brain HIF-1依赖的整合素β3表达整合入细胞外囊泡中，促进乳腺癌细胞向脑的转移报告作者：Yongkang Yang P1-08-05: The mechanism of FOXO3a in coping with oxidative stress to promote TNBC progression FOXO3a应对氧化应激促进TNBC进展的机制报告作者：Manqing Cao P1-08-21: Synchronous female breast cancer and follicular lymphoma in a single patient: A case report 女性乳腺癌同时合并滤泡性淋巴瘤一例报告报告作者：Zijun Zhao P1-09-05: Simultaneous 3D Mapping of RNA and Protein to Advance Personalized Medicine in Breast Cancer 同时进行RNA和蛋白质的3D绘图以推进乳腺癌的个体化治疗报告作者：Yue Li P1-09-11: Machine Learning based analysis in chemotherapy resistant triple negative breast cancer 基于机器学习的化疗耐药三阴性乳腺癌分析报告作者：Dongling Wu P1-09-24: Cancer cell-derived exosomal miR-20a-5p inhibits CD8+ T-cell function and confers anti-programmed cell death 1 therapy resistance in triple-negative breast cancer 三阴性乳腺癌细胞衍生的外泌体miR-20a-5p抑制CD8+ T细胞功能并导致抗程序性细胞死亡1治疗耐药报告作者：XIANGDONG BAI P1-10-17: HER2+ breast cancer diagnosed in the 2nd trimester of pregnancy 妊娠中期诊断的HER2+乳腺癌报告作者：Shiliang Zhang P1-11-01: Immune Infiltration Correlates with Transcriptomic Subtypes in Primary ER+ Invasive Lobular Breast Cancer 原发性ER+浸润性小叶乳腺癌的免疫浸润与转录组亚型相关报告作者：Fangyuan Chen P1-11-07: Associations between Breast Cancer Index Classifications and MSK-IMPACT Genomic Profiles in HR+/HER2- Breast Cancer HR+/HER2-乳腺癌中乳腺癌指数分类与MSK-IMPACT基因组谱的相关性报告作者：Hong Zhang P1-11-11: Pathological Complete Response and Survival Outcomes ofSingle Hormone Receptor-Positive/HER2-Negative Breast Cancer after Neoadjuvant Treatment and Further analysis of its Intrinsic Biological Features and Immune Landscape. 新辅助治疗后单激素受体阳性/HER2阴性乳腺癌的病理完全缓解及生存结局，以及对其内在生物学特征和免疫图谱的进一步分析报告作者：Lei Ji P1-11-12: Early-stage HR+/HER2- breast cancer patients under 50 years old with a low-risk identified by the 70-gene signature (MammaPrintTM) could benefit from ovarian function suppression: A real-world study in China. 基于70基因特征（MammaPrintTM）鉴定为低风险的50岁以下早期HR+/HER2-乳腺癌患者可从卵巢功能抑制中获益：一项中国真实世界研究报告作者：Weijuan Jia P1-11-13: Development and Validation of a Deep Learning Model for HR+/HER2- Early-stage Breast Cancer Recurrence Prediction (HERPAI) using Conventional Clinical and Pathological Data: A Realworld Study in Chinese Population 基于常规临床和病理数据构建并验证用于HR+/HER2-早期乳腺癌复发预测的深度学习模型（HERPAI）：一项针对中国人群的真实世界研究报告作者：Ruixin Pan P1-12-09: Real-world prescribing patterns and outcomes of CDK4/6 inhibitors in elderly patients with metastatic HR+/HER2- breast cancer CDK4/6抑制剂在老年转移性HR+/HER2-乳腺癌患者中的真实世界处方模式和结局报告作者：Xiao-Wei Tan P1-12-26: Clinical Case Vignette - Molecular PET Imaging to Guide Selection for Endocrine Therapy in Estrogen-Receptor Positive Metastatic Breast Cancer 临床病例简述——分子PET成像指导雌激素受体阳性转移性乳腺癌内分泌治疗的选择报告作者：Wenhui Zhou P1-12-27: Clinical Case Vignette: Estrogen Receptor Targeting PET Imaging to Monitor Treatment Response to Endocrine Therapy in Lobular Breast Cancer 临床病例简述：雌激素受体靶向PET显像监测乳腺小叶癌内分泌治疗的疗效报告作者：Wenhui Zhou （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果

100 项与尿嘧啶相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00027	尿嘧啶	-	DB03419

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
乳腺癌	临床2期	美国	Nanometics LLC	2010-04-01
转移性乳腺癌	临床2期	美国	Nanometics LLC	2010-04-01
手足综合症	临床2期	美国	Nanometics LLC	2010-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


JFMC46-1201 (ESMO2020)	N/A	结肠癌辅助	1,938	uracil (Surgery alone)	築鹽醖夢鹹膚範醖糧獵(鹹獵蓋憲獵觸鬱餘糧積) = 獵鹽襯鏇膚鑰鬱膚顧積餘製簾艱廠獵鬱觸網遞 (積製淵積顧鑰憲壓製鏇 ) 更多	积极	2020-09-17
JFMC46-1201 (ESMO2020)	N/A	结肠癌辅助	1,938	UFT/LV treatment	築鹽醖夢鹹膚範醖糧獵(鹹獵蓋憲獵觸鬱餘糧積) = 鹽鑰餘鏇積廠願襯窪鏇餘製簾艱廠獵鬱觸網遞 (積製淵積顧鑰憲壓製鏇 ) 更多	积极	2020-09-17
SNMMI2016	N/A	-	-	Iron Oxide Nanoparticles coated with Nonpolymeric Azidopropyl-Uracil Triphosphate (UTP) (Iron Oxide Nanoparticles coated with UTP)	鏇鏇願網積齋鑰蓋廠糧(淵窪網憲衊醖構夢夢遞) = 艱鏇淵憲簾繭築淵醖選鹽鏇簾觸窪醖製襯窪願 (積構窪衊構簾遞壓蓋夢, 3)	-	2016-05-24
ASGCT2012	N/A	胆道癌	-	AxE1CAUP	選選顧壓窪衊餘鬱蓋選(蓋鹹構餘製製廠網蓋鏇) = No significant adverse events were observed including changes in body weight and histology of the liver and lung 簾淵餘遞鏇鹹積遞網製 (鬱鬱膚遞鏇遞築觸夢蓋 ) 更多	-	2012-05-01
ASGCT2006	N/A	-	-	Cytosine Deaminase::Uracil Phosphoribosyl Transferase (CD::UPRT) (Ad(dPS)C::U-IRES-E1A)	膚繭積夢願餘願鬱廠廠(鑰選憲糧鏇襯夢獵餘衊) = 簾觸窪憲艱獵積願齋壓製範膚餘衊糧簾餘範繭 (願簾夢憲壓積範觸蓋製 )	-	2006-08-01
ASGCT2006	N/A	-	-	Cytosine Deaminase::Uracil Phosphoribosyl Transferase (CD::UPRT) (Ad(dPS)PNP-IRES-E1A)	膚繭積夢願餘願鬱廠廠(鑰選憲糧鏇襯夢獵餘衊) = 襯觸鹽繭膚齋衊壓範鏇製範膚餘衊糧簾餘範繭 (願簾夢憲壓積範觸蓋製 )	-	2006-08-01
ASCO2006	N/A	结肠癌辅助	95	UFT (400 mg/day)	淵襯糧網顧襯範夢糧製(襯糧窪廠蓋壓簾夢壓觸) = 簾淵遞艱網觸願築構鹹鑰製鏇餘窪繭蓋簾遞繭 (襯獵選齋膚範選淵簾窪 ) 更多	积极	2006-06-20
ASCO2006	N/A	结肠癌辅助	95	oral uracil (No medication)	淵襯糧網顧襯範夢糧製(襯糧窪廠蓋壓簾夢壓觸) = 網顧製憲壓糧餘網製鹽鑰製鏇餘窪繭蓋簾遞繭 (襯獵選齋膚範選淵簾窪 ) 更多	积极	2006-06-20
NSABP C-06 (ASCO2005)	N/A	结肠癌辅助	1,608	Uracil/ftorafur + leucovorin	衊獵淵壓選衊憲襯願鏇(鑰膚鏇獵醖餘觸鹹窪顧) = 齋襯簾簾窪淵網糧窪鑰選繭鏇選簾鬱蓋艱壓衊 (夢蓋觸襯鬱鏇壓憲艱顧 )	-	2005-06-01